Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking BioLife’s cryopreservation revenue or CGT logistics risks in a 300-page filing can drain hours. BioLife Solutions insider trading Form 4 transactions hide in dense tables, while critical 8-K updates on clinical-trial shipments surface without warning. If you have ever wondered, “How do I locate BioLife Solutions’ quarterly earnings report 10-Q filing in seconds?” Stock Titan delivers the answer.
Our platform ingests every submission the moment it hits EDGAR and feeds it to an AI engine that turns jargon into clarity. Need a BioLife Solutions annual report 10-K simplified? We highlight consumable sales growth, supply-chain quality metrics, and major risk factors. Looking for BioLife Solutions Form 4 insider transactions real-time? Instant alerts show which executives added shares. The AI also tags each BioLife Solutions proxy statement executive compensation section, unpacks option grants, and links them to performance goals. From BioLife Solutions earnings report filing analysis to a plain-English explainer of every BioLife Solutions 8-K material events explained, the information arrives ready to use.
Professionals rely on these insights to compare consumable-driven gross margins, monitor BioLife Solutions executive stock transactions Form 4 before therapy milestones, and evaluate liquidity through each BioLife Solutions SEC filings explained simply. Whether you are understanding BioLife Solutions SEC documents with AI for the first time or fine-tuning a DCF model, Stock Titan’s real-time coverage, AI-powered summaries, and historical archive of every filing form provide the edge you need—no more hunting through PDFs for the numbers that move CGT markets.
Casdin-related entities reported a 14.0% stake in BioLife Solutions (BLFS), owning 6,707,165 common shares based on 47,905,265 shares outstanding as of July 31, 2025. The shares are held by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin, who together share voting and dispositive power over the reported shares. The Reporting Persons state the shares were purchased for investment using the Fund's working capital and that no borrowed funds were used other than ordinary working capital borrowings. They state no current plans to pursue corporate control changes but reserve the right to recommend actions or cooperate with others to maximize shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of 500,000 shares of BioLife Solutions, Inc. (BLFS) on 08/15/2025 at a reported price of $24.40 per share. After the transaction, the Master Fund beneficially owned 6,707,165 shares, held indirectly. The Form 4 lists related reporting entities and individuals: Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin, each identified as a director or related to the Master Fund, and signatures are dated 08/21/2025. The filing includes a disclosure that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
BioLife Solutions, Inc. (BLFS) Rule 144 notice reports a proposed sale of 500,000 common shares through BMO Capital Markets on 08/15/2025 with an aggregate market value of $12,660,000. The filing states total shares outstanding of 47,905,265. The securities to be sold were acquired in three cash purchases: 250,000 on 07/02/2020, 100,000 on 12/16/2020, and 150,000 on 04/30/2024. The filer discloses prior sales by Casdin Partners Master Fund, L.P.: 1,000,000 shares on 06/10/2025 and 500,000 shares on 08/11/2025 with stated gross proceeds.
T. Rowe Price Investment Management, Inc. reports holding 4,246,706 shares of BioLife Solutions common stock, representing 8.9% of the class. The filing is a Schedule 13G filed by an investment adviser (classification IA) and indicates sole voting and sole dispositive power over those shares. The filer certifies the securities were acquired and are held in the ordinary course of business and states they were not acquired to change or influence control of the issuer. The filing also includes a declaration denying beneficial ownership in a closing certification.
Casdin-related reporting persons disclosed beneficial ownership of 7,207,165 shares of BioLife Solutions, Inc. That stake represents 15.0% of the company based on 47,905,265 shares outstanding as of July 31, 2025. The filing names Casdin Capital, LLC; Casdin Partners Master Fund, L.P.; Casdin Partners GP, LLC; and Eli Casdin as the reporting persons.
The filing states the Fund used its working capital to purchase the shares and did not use borrowed funds except for ordinary working capital borrowing. The Reporting Persons say they currently have no plans to change board composition, management, capitalization or dividend policy but reserve the right to propose or effect such changes and to engage with management and other shareholders about maximizing shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of BioLife Solutions, Inc. (BLFS) common stock on 08/11/2025. The filing shows a reported sale of 500,000 shares at a price of $22.60 per share. The transaction is recorded with transaction code S indicating a disposition.
The filing identifies related reporting entities—Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin—and states the securities are owned directly by the Master Fund and may be indirectly beneficially owned by those entities. After the reported transaction the reporting persons are shown as beneficially owning 7,207,165 shares indirectly.
BioLife Solutions (BLFS) Form 144 discloses a proposed sale of 500,000 shares of common stock through BMO Capital Markets on NASDAQ with an aggregate market value of $11,185,000. The filing reports 47,905,265 shares outstanding and an approximate sale date of 08/11/2025.
The shares were acquired on 12/16/2020 by purchase from a shareholder and paid in cash. The filing also lists a recent sale by Casdin Partners Master Fund, L.P. of 1,000,000 shares on 06/10/2025 for $23,800,000. The seller certifies they are unaware of any undisclosed material adverse information.
BioLife Solutions Inc. (BLFS) – Form 4 filing: Chief Human Resources Officer Sarah Aebersold sold 198 shares of common stock on 7 July 2025 at $22.27 per share under a pre-established Rule 10b5-1 trading plan. The sale was executed to cover tax-withholding obligations associated with previously vested restricted stock. After the transaction, the officer still owns 78,523 shares, which continue to be held directly. No derivative security activity was reported.
The transaction represents <0.3% of the insider’s total direct holdings and does not indicate a change in her overall investment thesis or role at the company. As such, the filing is considered routine and of low financial materiality for most investors.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
